Article Information
PMID
Published By
Print ISSN
0250-7005
Online ISSN
1791-7530
History
- Received September 29, 2003
- Accepted February 18, 2004
- Published online March 1, 2004.
Copyright & Usage
Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
Author Information
- ANNE BETHUNE-VOLTERS1,
- MARC LABROQUERE2,
- SYLVIE GUEPRATTE2,
- KAMEL HACENE3,
- RAINER NEUMANN4,
- WALTER CARNEY5 and
- MARIE-FRANCE PICHON2
- 1Service d' Oncologie Médicale, Centre René Huguenin de Lutte Contre le Cancer, 35 rue Dailly, 92 210 Saint-Cloud, France
- 2Laboratoire d' Oncobiologie, service de Médecine Nucléaire, Centre René Huguenin de Lutte Contre le Cancer, 35 rue Dailly, 92 210 Saint-Cloud, France
- 3Service de Statistiques Médicales, Centre René Huguenin de Lutte Contre le Cancer, 35 rue Dailly, 92 210 Saint-Cloud, France
- 4Bayer Vital GmbH, Leverkusen, Germany
- 5Oncogene Science/Bayer Diagnostics, Cambridge, MA 02142-1168, U.S.A.
- Correspondence to: Dr. M.-F. Pichon, Laboratoire d' Oncobiologie, service de Médecine Nucléaire, Centre René Huguenin de Lutte Contre le Cancer, 35 rue Dailly, 92 210 Saint-Cloud, France. Tel: +33 147111574, Fax: +33 147111573, e-mail: mf.pichon{at}stcloudhuguenin.org
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients
- Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy
- Comparison of Pre- and Postsurgical Concentrations of Blood HER-2 mRNA and HER-2 Extracellular Domain Reflects HER-2 Status in Early Breast Cancer